GILD vs VRTX

• GILDBuy more18%

  Gilead Sciences' report on Oct 29 beat profit forecasts by 18%, and it pays a 2% dividend that it has raised for 10 years in a row.

• VRTXBuy moresales growth, past year10%

  Vertex Pharmaceuticals' sales grew 10% over the past year, and three more analysts rate it a buy than three months ago.

Percent return

• GILD+41.91%
• VRTX+27.45%

1M6MYTD1Y5YMax

Nov 11, 2025 to Nov 11, 2026

Where they differ

Even, 2 each of 6

GILDVRTX

• Company size: GILD $165B, VRTX $122B.
  $165BbiggerCompany size$122B
• Sales growth, 1 yr: GILD +6.5%, VRTX +10%. VRTX is ahead.
  +6.5%Sales growth, 1 yr+10%
• Price for $1 of next year's profit: GILD $20, VRTX $29. GILD is ahead.
  $20cheaperPrice for $1 of next year's profit$29
• Profit per $1 of sales: GILD 38¢, VRTX 38¢.
  38¢Profit per $1 of sales38¢
• Cash minus debt: GILD −$18.3B, VRTX +$3.34B. VRTX is ahead.
  −$18.3BCash minus debt+$3.34B
• Price change, 1 yr: GILD +42%, VRTX +27%. GILD is ahead. S&P 500 +12%.
  +42%Price change, 1 yr+27%
• How much the price swings: GILD 28%, VRTX 28%.
  28%How much the price swings28%

Measure	GILDGilead Sciences	VRTXVertex Pharmaceuticals
Price and returns
Price	$169.74	$547.18
Today	−0.66%	Best in this row: −0.13%
1 month	Best in this row: +12.28%	+7.24%
3 months	Best in this row: +25.72%	+3.31%
This year	Best in this row: +40.77%	+20.66%
1 year	Best in this row: +41.91%	+27.45%
5 years	Best in this row: +200.78%	+194.31%
From 52-week high	−2.7%	−2.1%
How much it swings (90 days)	Best in this row: 28%	28%
Valuation
Market value	$165B	$122B
Price vs last year's earnings	Best in this row: 18.1×	28.6×
Price vs next year's expected earnings	Best in this row: 20.0×	29.0×
Price vs earnings, adjusted for growth	Best in this row: 1.46×	2.11×
Price to sales	Best in this row: 6.7×	10.7×
Price vs cash it brings in	Best in this row: 15.0×	43.3×
Company value vs operating profit	Best in this row: 15.4×	26.5×
Growth
Revenue growth, 1 year	+6.5%	Best in this row: +10.5%
Revenue growth a year, last 3 years	+2.6%	Best in this row: +10.3%
Earnings per share growth, last year	+55.0%	Best in this row: +546.5%
Earnings per share growth expected next year	Best in this row: +1290.9%	+10.4%
Profitability
Kept from sales after making the product	Best in this row: 80.0%	54.8%
Kept as operating profit	Best in this row: 38.2%	37.8%
Kept as final profit	−12.5%	Best in this row: 30.7%
Kept as spare cash	Best in this row: 44.5%	24.7%
Profit on shareholders' money	−22.4%	Best in this row: 20.8%
Profit on all money put in	Best in this row: 36.8%	23.1%
Balance sheet
Net cash (cash minus debt)	−$18.3B	Best in this row: $3.34B
Debt for each $1 of shareholders' money	2.02×	Best in this row: 0.31×
Short-term assets per $1 of bills due	1.38×	Best in this row: 2.34×
Dividend yield	1.97%	–
Our readPro
Our call	Buy more	Buy more
Why	Gilead Sciences' report on Oct 29 beat profit forecasts by 18%, and it pays a 2% dividend that it has raised for 10 years in a row.	Vertex Pharmaceuticals' sales grew 10% over the past year, and three more analysts rate it a buy than three months ago.
Where the price sits	in the full report	in the full report
Our overall score (out of 100)	73	Best in this row: 73
Our value score	Best in this row: 91	60
Our growth score	70	Best in this row: 74
Our quality score	Best in this row: 90	90
Our price trend score	48	Best in this row: 70
Earnings and analysts
Analyst consensus	Buy	Buy
To average analyst target	+1.9%	Best in this row: +12.6%
Average analyst target	$172.95	$616.37
Analysts rating it a buy	79%	Best in this row: 81%
Buy ratings added, 3 months	0	Best in this row: +3
Analysts covering	22	22

VRTX: faster sales growth

Our pick of these: Vertex Pharmaceuticals

Buy more68/100

Sales growth +10.5% vs +6.5%

GILD +6.5%, VRTX +10.5%.

GILD+6.5%

VRTX+10.5%

Forward P/E per point of sales growth 2.77 vs 3.05

GILD 3.05, VRTX 2.77.

GILD3.05

VRTX2.77

+12.6% to the average analyst target, vs +1.9%

GILD +1.9%, VRTX +12.6%.

GILD+1.9%

VRTX+12.6%

Where it loses: GILD has a better past year, +41.9% vs +27.4%

• 2ndGILDBuy more32/100Would need faster sales growth, +6.5% vs +10.5%

Prices as of yesterday, 3:59 PM ET. A view, not advice.